Evommune says Phase 2a trial shows EVO301 cuts EASI 55% at Week 12 in atopic dermatitis

By Public Technologies
  • Evommune presented additional Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.
  • Trial results showed clear symptom improvement versus placebo, with responses continuing to build weeks after the second dose.
  • Safety profile was broadly comparable to placebo, supporting further development and differentiation from existing biologics.
  • Plans set to start a global, dose-optimized Phase 2b trial using a subcutaneous formulation in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001558140) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.